Clinical Trials Logo

Syringomyelia clinical trials

View clinical trials related to Syringomyelia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06308367 Recruiting - Syringomyelia Clinical Trials

The Therapeutic Effect of Betaine in Syringomyelia

Start date: March 2024
Phase: Phase 2
Study type: Interventional

Purpose: This clinical trial aims to evaluate the indications, therapeutic effects and side effects of betaine in refractory syringomyelia. Primary outcome measure: The primary endpoint is the change of ASIA at week 12. The clinical efficacy is defined as ASIA increase ≥ 1 at week 12, as compared with that before betaine usage.

NCT ID: NCT06268093 Recruiting - Syringomyelia Clinical Trials

The Therapeutic Effect of Thalidomide in Syringomyelia

Start date: February 2024
Phase: Phase 2
Study type: Interventional

Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects and side effects of thalidomide in refractory syringomyelia. Primary outcome measure: The primary endpoint is the change of ASIA at week 12. The clinical efficacy is defined as ASIA increase ≥ 1 at week 12, as compared with that before thalidomide usage.

NCT ID: NCT04856839 Recruiting - Clinical trials for Syringomyelia/Hydromyelia

Clinical Outcome in Patients With Syringomyelia(COPSM)

Start date: April 16, 2021
Phase:
Study type: Observational

The aim of this study is to determine the clinical spectrum and natural progression of Syringomyelia (SM) and related disorders in a prospective single center study, identify digital, imaging and molecular biomarkers that can assist in diagnosis and therapy development and study the etiology and molecular mechanisms of these diseases.